Bone Biologics Corp.
13F holders, Q3 2024 (September 30)7holders +2
2new positions
0sold out
$2.13avg. 13F price*
At the end of Q3 2024, 7 institutions reported holding Bone Biologics Corp. in their 13F filings, up 2 from Q2 2024. 2 opened new positions and 0 sold out. The largest holders were UBS Group AG ($70K), Morgan Stanley ($61K) and HRT Financial LP ($47K).
- Company
- Bone Biologics Corp.
- CUSIP
- 098070501
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $62K |
| Exits | 0 | $0 |
All 13F filers, Q2 2024 → Q3 2024: 33,733 shares bought and 4,859 shares sold, net +28,874 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| UBS Group AG | 0.00% | Reduce -2.5% | 32,851 | $70K |
| Morgan Stanley | 0.00% | New | 28,527 | $61K |
| HRT Financial LP | 0.00% | Add +27.1% | 22,276 | $47K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -69.2% | 1,786 | $4K |
| Cwm, LLC | 0.00% | New | 444 | $1K |
| Mfa Wealth Advisors, LLC | 0.00% | No change | 403 | $858 |
| Bank of America Corp. | 0.00% | Add +55.6% | 14 | $30 |
"% of holder's portfolio" is BONE BIOLOGICS CORP's weight in each manager's 13F, not the share of Bone Biologics Corp. the manager owns.